1.23
Schlusskurs vom Vortag:
$1.26
Offen:
$1.28
24-Stunden-Volumen:
62,614
Relative Volume:
0.08
Marktkapitalisierung:
$4.95M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.56M
KGV:
-0.2332
EPS:
-5.274
Netto-Cashflow:
$-7.76M
1W Leistung:
+4.24%
1M Leistung:
-0.81%
6M Leistung:
-59.41%
1J Leistung:
-83.47%
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Firmenname
Dermata Therapeutics Inc
Sektor
Branche
Telefon
(858)-223-0882
Adresse
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
DRMA
Dermata Therapeutics Inc
|
1.23 | 5.07M | 0 | -7.56M | -7.76M | -5.274 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dermata Therapeutics Inc Aktie (DRMA) Neueste Nachrichten
DRMA Q1 2026 Earnings: Narrower Loss Than Expected Bolsters Investor SentimentRevenue Report - Newser
Dermata Therapeutics (NASDAQ: DRMA) files $100M shelf for stock, warrants - Stock Titan
DRMA Technical Analysis | Trend, Signals & Chart Patterns | DERMATA THERAPEUTICS INC (NASDAQ:DRMA) - ChartMill
Dermata Therapeutics (DRMA) Slides 0.8% as Shares Hover Near Support at $1.18Virgin POC - Newser
Dermata Therapeutics Warrant (DRMAW) Holds at $0.01 as Trading Remains FlatGap Fill Strategy - Newser
Dermata shares rise after USPTO issues patent notice of allowance - MSN
Dermata Therapeutics, Inc.Common Stock (NQ: DRMA - FinancialContent
DRMA Should I Buy - Intellectia AI
Inhibikase Therapeutics, Inc.Common Stock (NQ: IKT - FinancialContent
DRMA Stock Chart | DERMATA THERAPEUTICS INC (NASDAQ:DRMA) - ChartMill
DRMA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Dermata Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Dermata Therapeutics (NASDAQ:DRMA) Q1 2026 Earnings: Narrowing Losses and Strategic Pivot to DTC Skincare - ChartMill
Intracoastal-linked holders report 4.99% stake in Dermata (NASDAQ: DRMA) - Stock Titan
Once-weekly Tome mask aims to bring professional skincare home by mid-2026 - Stock Titan
[10-Q] Dermata Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Dermata Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Dermata (NASDAQ: DRMA) advances DTC pivot in Q1 2026 update - Stock Titan
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026 - Yahoo Finance
TradingKey - TradingKey
What Dermata (DRMAW) flagged as biggest challenges ahead | DRMAW Q3 Earnings: Dermata Warrant Reports No Revenue or Earnings DataCommunity Sell Signals - Newser
Dermata Therapeutics Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Dermata Therapeutics Inc. (DRMA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
DRMAW Dermata quarterly earnings core metrics remain unavailable as investors await full official operational and financial disclosures.Forward Guidance - newser.com
DRMAW SEC FilingsDermata Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RBC Capital initiates Dermata Therapeutics stock at outperform By Investing.com - Investing.com South Africa
RBC Capital initiates Dermata Therapeutics stock at outperform - Investing.com
Dermata (DRMA) Stock Valuation | Dermata Therapeutics posts narrower loss, 3.2 pct EPS beatSurprise Factor - Cổng thông tin điện tử tỉnh Lào Cai
Bigger Capital now holds 75,200 shares after sales (NASDAQ: DRMA) - Stock Titan
Dermata (DRMA) Stock Hot Topic (Institutional Selling) 2026-04-20Analyst Consensus - Cổng thông tin điện tử tỉnh Lào Cai
Dermata Therapeutics (NASDAQ: DRMA) seeks approval for warrants and equity plan at 2026 meeting - Stock Titan
Patterns Watch: Does LogProstyle Inc have strong fundamentalsDip Buying & Expert Approved Momentum Ideas - baoquankhu1.vn
Sentiment Watch: Will Dermata Therapeutics Inc Equity Warrant outperform the market in YEARWeekly Trade Analysis & High Accuracy Swing Trade Signals - baoquankhu1.vn
Are investors bearish on Dermata (DRMA) Stock | Price at $1.25, Up 2.87%Large Cap Trends - Xã Vĩnh Công
WSBCO Should I Buy - Intellectia AI
Bond Watch: Is Dermata Therapeutics Inc Equity Warrant stock risky to hold nowRate Cut & Precise Swing Trade Alerts - baoquankhu1.vn
Moving Averages: Is Dermata Therapeutics Inc Equity Warrant gaining market share2026 Institutional & Verified Technical Signals - baoquankhu1.vn
Market Review: Will Dermata Therapeutics Inc benefit from AI trendsEntry Point & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Can Dermata (DRMA) Stock Go Higher | Price at $1.24, Up 2.07%Viral Trade Signals - Newser
Aug Sectors: Is Dermata Therapeutics Inc Equity Warrant benefiting from innovation trendsTrade Exit Report & Weekly Top Gainers Trade List - baoquankhu1.vn
Targets Report: Is Dermata Therapeutics Inc Equity Warrant stock undervalued right nowWeekly Stock Report & Daily Volume Surge Signals - baoquankhu1.vn
What limits growth of Xeris (XERS) Stock | XERS Q4 Earnings: Beats Estimates by $0.02Community Risk Signals - Cổng thông tin điện tử tỉnh Lào Cai
Gap Down: Will Bukit Jalil Global Acquisition 1 Ltd Equity Warrant benefit from green energy policies2026 Trends & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Analyst Calls: Whats the outlook for Dermata Therapeutics Incs sector2026 Price Targets & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
[PRE 14A] Dermata Therapeutics, Inc. Preliminary Proxy Statement - Stock Titan
Take Profit: Is Dermata Therapeutics Inc Equity Warrant benefiting from innovation trendsQuarterly Risk Review & Reliable Intraday Trade Plans - baoquankhu1.vn
Market Moves: Can Dermata Therapeutics Inc Equity Warrant weather a recessionRate Hike & Smart Investment Allocation Insights - baoquankhu1.vn
Is Dermata (DRMA) Stock Losing Momentum | Price at $1.32, Up 2.33%Low Beta Factor - Newser
CAS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ALYAF Should I Buy - Intellectia AI
DRMA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Finanzdaten der Dermata Therapeutics Inc-Aktie (DRMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):